Research and Markets: Impetigo Global Clinical Trials Review, Q1, 2011

DUBLIN--(BUSINESS WIRE)-- Research and Markets(http://www.researchandmarkets.com/research/3b564e/impetigo_global_cl) has announced the addition of GlobalData 's new report "Impetigo Global Clinical Trials Review, Q1, 2011" to their offering.

Our clinical trial report, Impetigo Global Clinical Trials Review, Q1, 2011" provides data on the Impetigo clinical trial scenario. This report provides in-depth information and data relating to the clinical trials on Impetigo. It includes an overview of the trial numbers and their recruitment status as per the site of trial development throughout the world, focusing on the status of participation by the developing nations. It offers coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides information pertaining to the number of trials for the key drugs for treating Impetigo. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

Scope

  • Data on the number of clinical trials conducted in North America, South And Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status and trial success rate
  • Review of key discontinued trials (suspended, withdrawn and terminated)

Key Topics Covered:

  • Introduction
  • Impetigo
  • Report Guidance
  • Clinical Trials by Region
  • Clinical Trials by Country
  • Top Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by BRIC Nations
  • Clinical Trials by Phase
  • Clinical Trials by Trial Status
  • Unaccomplished Trials of Impetigo
  • Subjects Recruited Over a Period of Time
  • Prominent Sponsors
  • Top Companies Participating in Impetigo Therapeutics Clinical Trials
  • Prominent Drug Comparison
  • Clinical Trial Profiles

For more information visit http://www.researchandmarkets.com/research/3b564e/impetigo_global_cl



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Clinical Trials

MEDIA:

Logo
 Logo

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.